Abstract

Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), previously known as “Baboon Syndrome,” is diagnosed if four or more of the following criteria are met: symmetry, involvement of at least one intertriginous zone, erythema of the gluteal, inguinal, or axillary region, systemic exposure to a drug, and lack of systemic toxicity. A first ever case of SDRIFE after HSCT is presented who was initially treated for multiple recurrences of acute skin graft versus host disease. SDRIFE should be considered in the differential diagnosis of refractory GvHD and is easily treatable by avoiding the offending medication.